Agricultural Pheromone Market By Crop Type (Field Crops, Fruit and Vegetables, Ornamental Plants, Others) , By Function (Mass Trapping, Mating Disruption, Monitoring and Detection) By Mode of Application (Traps, Dispensers, Sprays, Pheromone-Impregnated Materials) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The agricultural pheromone market was valued at $3.8 billion in 2023, and is projected t%li%reach $17.9 billion by 2033, growing at a CAGR of 16.7% from 2024 t%li%2033.
Agricultural pheromones are chemicals that are used for effective and sustainable pest management. They work by disrupting the pest's ability t%li%mate, inhibiting the growth of from destroying crops. They serve as a valuable tool in pest management as they specifically target pests and minimize environmental impact.
The growth of the global agricultural pheromone market is majorly driven by increase in environmental concerns associated with the use of chemical-based pesticides and surge in preference of farmers toward sustainable farming practices. Moreover, implementation of stringent government regulations toward chemical pesticides promotes the growth of the market. For instance, the Environmental Protection Agency (EPA) has enforced many programs and strategies t%li%ensure safe level of exposure t%li%the residues of pesticides that may remain on food. For instance, Pesticide Residue Monitoring Program monitors and regulates that pesticide residues are present within the allowable tolerance level. Such regulations limit the adoption of chemical pesticides and promote the use of pheromones, which significantly contributes toward the growth of the global market. However, insects exhibit the potential t%li%develop resistance against pheromones similar t%li%how they become resistant t%li%chemical pesticides, which restrains the growth of the market. In addition, pheromones can be costly t%li%produce and apply as compared t%li%traditional chemical pesticides. Extensive initial setup requirements including dispensers and monitoring equipment, incur additional cost, which acts as a key deterrent factor of the market. Moreover, the species-specific nature of pheromones attract or repel certain types of insects or pests, which limits their effectiveness against multiple pests, thus hampering the market growth. On the contrary, ongoing research int%li%new formulations and delivery methods for pheromones such as microencapsulation, slow-release formulations, and novel dispensing systems improve effectiveness and longevity, which is expected t%li%open new avenues for the expansion of the market in the coming future.
The agricultural pheromone market forecast is segmented int%li%crop type, function, mode of application, and region. On the basis of crop type, the market is classified int%li%field crops, fruit & vegetables, ornamental plants, and others. By function, it is categorized int%li%mass trapping, mating disruption, and monitoring & detection. Depending on mode of application, it is fragmented int%li%traps, dispensers, sprays, and pheromone-impregnated materials. Region-wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of crop type, the field crops segment is expected t%li%dominate the market by 2033.
By function, the mating disruption segment is expected t%li%lead throughout the forecast period.
Depending on mode of application, the dispensers segment is anticipated t%li%gain high prominence in the coming years.
Region wise, Asia-Pacific is likely t%li%maintain its dominance by 2033.
Competition Analysis
Competitive analysis and profiles of the major players in the global agricultural pheromone market include FMC Corporation, Ephytia, BASF SE, MITSUI & CO., LTD, Biobest Group NV, Russell IPM, ISCA, Trйcй Inc, BedoukianBio, Pherobank These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, which help t%li%garner maximum share in the agricultural pheromone market and sustain intense competition.
Additional benefits you will get with this purchase are:
By Crop Type
Agricultural pheromones are chemicals that are used for effective and sustainable pest management. They work by disrupting the pest's ability t%li%mate, inhibiting the growth of from destroying crops. They serve as a valuable tool in pest management as they specifically target pests and minimize environmental impact.
The growth of the global agricultural pheromone market is majorly driven by increase in environmental concerns associated with the use of chemical-based pesticides and surge in preference of farmers toward sustainable farming practices. Moreover, implementation of stringent government regulations toward chemical pesticides promotes the growth of the market. For instance, the Environmental Protection Agency (EPA) has enforced many programs and strategies t%li%ensure safe level of exposure t%li%the residues of pesticides that may remain on food. For instance, Pesticide Residue Monitoring Program monitors and regulates that pesticide residues are present within the allowable tolerance level. Such regulations limit the adoption of chemical pesticides and promote the use of pheromones, which significantly contributes toward the growth of the global market. However, insects exhibit the potential t%li%develop resistance against pheromones similar t%li%how they become resistant t%li%chemical pesticides, which restrains the growth of the market. In addition, pheromones can be costly t%li%produce and apply as compared t%li%traditional chemical pesticides. Extensive initial setup requirements including dispensers and monitoring equipment, incur additional cost, which acts as a key deterrent factor of the market. Moreover, the species-specific nature of pheromones attract or repel certain types of insects or pests, which limits their effectiveness against multiple pests, thus hampering the market growth. On the contrary, ongoing research int%li%new formulations and delivery methods for pheromones such as microencapsulation, slow-release formulations, and novel dispensing systems improve effectiveness and longevity, which is expected t%li%open new avenues for the expansion of the market in the coming future.
The agricultural pheromone market forecast is segmented int%li%crop type, function, mode of application, and region. On the basis of crop type, the market is classified int%li%field crops, fruit & vegetables, ornamental plants, and others. By function, it is categorized int%li%mass trapping, mating disruption, and monitoring & detection. Depending on mode of application, it is fragmented int%li%traps, dispensers, sprays, and pheromone-impregnated materials. Region-wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of crop type, the field crops segment is expected t%li%dominate the market by 2033.
By function, the mating disruption segment is expected t%li%lead throughout the forecast period.
Depending on mode of application, the dispensers segment is anticipated t%li%gain high prominence in the coming years.
Region wise, Asia-Pacific is likely t%li%maintain its dominance by 2033.
Competition Analysis
Competitive analysis and profiles of the major players in the global agricultural pheromone market include FMC Corporation, Ephytia, BASF SE, MITSUI & CO., LTD, Biobest Group NV, Russell IPM, ISCA, Trйcй Inc, BedoukianBio, Pherobank These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, which help t%li%garner maximum share in the agricultural pheromone market and sustain intense competition.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting t%li%16 analyst hours t%li%solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent t%li%3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Investment Opportunities
- Product Life Cycles
- Upcoming/New Entrant by Regions
- Technology Trend Analysis
- Distributor margin Analysis
- Market share analysis of players by products/segments
- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific t%li%client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- Market share analysis of players at global/region/country level
- Product Consumption Analysis
- SWOT Analysis
- Volume Market Size and Forecast
By Crop Type
- Field Crops
- Fruit and Vegetables
- Ornamental Plants
- Others
- Mass Trapping
- Mating Disruption
- Monitoring and Detection
- Traps
- Dispensers
- Sprays
- Pheromone-Impregnated Materials
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
- Key Market Players
- FMC Corporation
- Ephytia
- BASF SE
- MITSUI & CO., LTD
- Biobest Group NV
- Russell IPM
- ISCA
- Trйcй Inc
- BedoukianBio
- Pherobank
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4: HEART ATTACK DIAGNOSTICS MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Electrocardiogram
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Blood Tests
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Angiogram
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Computerized Cardiac Tomography
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
CHAPTER 5: HEART ATTACK DIAGNOSTICS MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Diagnostics Centers
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Others
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: HEART ATTACK DIAGNOSTICS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Heart Attack Diagnostics Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Heart Attack Diagnostics Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Heart Attack Diagnostics Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. France Heart Attack Diagnostics Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. Germany Heart Attack Diagnostics Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. Italy Heart Attack Diagnostics Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Spain Heart Attack Diagnostics Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. UK Heart Attack Diagnostics Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest of Europe Heart Attack Diagnostics Market
6.3.10.1. Market Size and Forecast, By Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. China Heart Attack Diagnostics Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. Japan Heart Attack Diagnostics Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. India Heart Attack Diagnostics Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. South Korea Heart Attack Diagnostics Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. Australia Heart Attack Diagnostics Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Heart Attack Diagnostics Market
6.4.10.1. Market Size and Forecast, By Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Heart Attack Diagnostics Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. South Africa Heart Attack Diagnostics Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. Saudi Arabia Heart Attack Diagnostics Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Heart Attack Diagnostics Market
6.5.8.1. Market Size and Forecast, By Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Bionet Co., Ltd
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. TOSHIBA CORPORATION
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Bio-Rad Laboratories Inc
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Life Sign LLC
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Schiller AG
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Beckman Coulter, Inc.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. GE Healthcare
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Hitachi Medical Systems
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. F. Hoffmann-La Roche Ltd.
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Abbott Laboratories
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4: HEART ATTACK DIAGNOSTICS MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Electrocardiogram
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Blood Tests
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Angiogram
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Computerized Cardiac Tomography
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
CHAPTER 5: HEART ATTACK DIAGNOSTICS MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Diagnostics Centers
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Others
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: HEART ATTACK DIAGNOSTICS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Heart Attack Diagnostics Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Heart Attack Diagnostics Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Heart Attack Diagnostics Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. France Heart Attack Diagnostics Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. Germany Heart Attack Diagnostics Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. Italy Heart Attack Diagnostics Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Spain Heart Attack Diagnostics Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. UK Heart Attack Diagnostics Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest of Europe Heart Attack Diagnostics Market
6.3.10.1. Market Size and Forecast, By Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. China Heart Attack Diagnostics Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. Japan Heart Attack Diagnostics Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. India Heart Attack Diagnostics Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. South Korea Heart Attack Diagnostics Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. Australia Heart Attack Diagnostics Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Heart Attack Diagnostics Market
6.4.10.1. Market Size and Forecast, By Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Heart Attack Diagnostics Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. South Africa Heart Attack Diagnostics Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. Saudi Arabia Heart Attack Diagnostics Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Heart Attack Diagnostics Market
6.5.8.1. Market Size and Forecast, By Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Bionet Co., Ltd
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. TOSHIBA CORPORATION
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Bio-Rad Laboratories Inc
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Life Sign LLC
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Schiller AG
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Beckman Coulter, Inc.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. GE Healthcare
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Hitachi Medical Systems
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. F. Hoffmann-La Roche Ltd.
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Abbott Laboratories
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
